MNTK is Montauk Renewables, Inc., the Pittsburgh-based company that captures methane from landfills and turns it into renewable natural gas or electricity. Because the shares have advanced sharply, published analyst targets no longer serve as straightforward upside forecasts. Four current, attributable targets—Scotiabank at $2.00, Clear Street at $3.00 (a Buy), UBS at $1.60, and B. Riley at $1.50—average roughly $2.03, well under the $2.78 market price. Only one target exceeds the current quote, so no meaningful consensus upside can be derived. The $3.30 level referenced here therefore originates from technical discussion, specifically retesting and clearing the 52-week high of $3.28 set on October 5, 2026.
At the verified close of $2.78, MNTK trades more than 160% above its March 2026 low and sits just below its 52-week high. The move to $3.30 equates to about 18.7%, a sizable gain that would require breaking through clear overhead resistance. The stock remains above its 50-day average near $2.41 and 200-day average near $1.77, confirming the longer-term uptrend, yet the $3.27–$3.30 zone stands as the most immediate supply area. A sustained advance would likely need continued RIN-price strength, another earnings beat, and affirmation of the $198 million to $216 million revenue guidance.
Montauk’s revenue ties closely to RIN values—tradeable credits tied to RNG—along with state and federal clean-fuel programs. Recovering RIN prices have driven much of the recent rebound. Second-quarter sales of approximately $46.4 million topped consensus by more than 7% and rose about 9% year over year. Management’s FY2026 guidance points to solid top-line growth, and consensus estimates anticipate rising revenue and EBITDA through 2027. Sustained demand for RNG as a low-carbon fuel and any positive regulatory moves could help maintain the uptrend. I also checked this using Tickeron’s AI Screener to see how the stock compares within the sector.
The primary concern remains a reversal in RIN pricing, which has proven volatile and sensitive to policy shifts. The company faces sizable capital-expenditure needs and negative free cash flow, factors that have weighed on EBITDA growth and led several analysts to lower targets during 2026. Profitability stays thin, with trailing EPS near $0.06, leaving the stock at a trailing P/E around 45x and offering limited valuation cushion. In addition, most sell-side targets sit below the current price, indicating that much of the recent optimism may already be priced in.
The key technical markers are the 52-week high of $3.28 and the round-number $3.30 zone immediately above it, which together define primary resistance. Support rests near the 50-day moving average around $2.41, with deeper support near the 200-day average around $1.77. A 14-day RSI near 61 points to constructive yet not overbought momentum. The sharp November rebound shows buyers defending the trend, but the path to $3.30 still runs through a prior peak that has already capped prices once.
Analyst targets generally reflect a roughly 12-month outlook, while the technical $3.30 objective carries no set timeframe. Investors should track quarterly earnings and guidance, monthly RIN index pricing, capital-expenditure and free-cash-flow trends, any updates to federal Renewable Fuel Standard or state clean-fuel programs, and shifts in analyst ratings or targets. These factors will determine whether the rally from $1.07 carries enough fundamental backing to clear the $3.30 level.
Tickeron’s AI Daily Buy/Sell Signals apply artificial intelligence to monitor thousands of stocks and ETFs in real time, producing Buy, Sell, or Hold signals based on evolving market conditions and technical behavior. For a name like MNTK, the tool helps identify potential shifts in trend and assists with entry or exit decisions more efficiently than manual review. I find it useful for staying on top of volatile holdings without constant screen time.
Whether MNTK can reach $3.30 depends on whether recovering RIN economics can push through technically significant resistance at the 52-week high. The required 18.7% advance is substantial. While revenue guidance, the recent sales beat, and the established uptrend offer support, thin profitability, ongoing capital spending, and a cautious analyst stance—with most targets below the current price—present real hurdles. I view $3.30 as a technical level to test rather than a guaranteed outcome, and continued monitoring of RIN pricing and earnings momentum will be essential.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The Moving Average Convergence Divergence (MACD) for MNTK turned positive on November 02, 2026. Looking at past instances where MNTK's MACD turned positive, the stock continued to rise in 47 of 54 cases over the following month. The odds of a continued upward trend are 87%.
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on MNTK as a result. In 74 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
MNTK moved above its 50-day moving average on November 02, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for MNTK crossed bullishly above the 50-day moving average on November 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 73%.
Following a +15.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where MNTK advanced for three days, in 221 of 270 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
The Aroon Indicator entered an Uptrend today. In 153 of 176 cases where MNTK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 87%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MNTK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
MNTK broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. MNTK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 69 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.464) is normal, around the industry mean (2.284). P/E Ratio (54.400) is within average values for comparable stocks, (-17.137). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.548). Dividend Yield (0.000) settles around the average of (0.039) among similar stocks. P/S Ratio (1.709) is also within normal values, averaging (48.960).
The Tickeron SMR rating for this company is 87 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 93 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MNTK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry ChemicalsSpecialty